Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 10 other studies
people with cardiovascular disease, in this paper
Among patients with established or a risk of cardiovascular disease, the trial randomly assignedassigned by chance
semaglutide
placebo
May have lowered major heart events−19%
randomised · one subgroup, may be chanceAmong all patients, the trial randomly assignedassigned by chance
semaglutide
placebo
May have lowered expanded MACE−20%
randomised · one subgroup, may be chancethe abstract, start to end
… cardiovascular disease (risk ratio [RR] 0.81; 95% confidence interval [CI] …
… significantly with semaglutide (RR 0.80; 95% CI 0.75-0.86; p < …
… reduction was significant in males (RR 0.78; 95% CI 0.70-0.87; p < 0.00001) …
← favours treatmentfavours comparator →
could be chanceMajor adverse cardiovascular events (MACE)semaglutide vs placebo, in patients with established or a risk of cardiovascular disease
RR 0.810.74–0.88
Expanded MACEsemaglutide vs placebo, in all patients
RR 0.800.75–0.86
Major adverse cardiovascular events (MACE)semaglutide vs placebo, in males
RR 0.780.70–0.87
GLP-1 receptor agonistsCardiovascular events
GLP-1 receptor agonists × cardiovascular eventshelps?mixed
unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
1 / 6